ESC Premium Access

Adverse events in patients with LDL-C <0.65 mmol/L (<25 mg/dL) or <0.39 mmol/L (<15 mg/dL) during alirocumab treatment for up to 104 weeks: data from 14 randomized trials

Topic: Primary cardiovascular prevention: interventions and outcomes

Presentation

About the speaker

Doctor Jennifer Robinson

University of Iowa, Iowa (United States of America)
12 presentations
0 follower

19 more presentations in this session

Nurse-led telephone-based follow-up of secondary prevention after acute myocardial infarction: one-year results from the randomized controlled NAILED-ACS trial.

Speaker: Doctor D. Huber (Umea, SE)

Thumbnail

Six sigma approach to reduce door-to-balloon time for patients with ST-elevation myocardial infarction undergoing primary PCI

Speaker: Doctor T. Sharma (Baltimore, US)

Thumbnail

Evolution of European Society of Cardiology Guidelines since 2000: a systematic appraisal

Speaker: Doctor C. Badu-Boateng (Frimley, GB)

Thumbnail

Inhibition of acetylcholinesterase by bromide pyridostigmine prevents ventricular dysfunction, autonomic and reduce inflammatory profile in rats treated previously to myocardial infarction

Speaker: Ms C. Barboza (Sao Paulo, BR)

Thumbnail

Antihypertensive and anti-inflammatory effects of pentoxifylline? A Systematic review and meta-analysis of randomized controlled trials

Speaker: Doctor D. Brie (Timisoara, RO)

Thumbnail

Access the full session

Poster session 2 - Cardiovascular prevention outcomes I

Speakers: Doctor J. Robinson, Doctor D. Huber, Doctor T. Sharma, Doctor C. Badu-Boateng, Ms C. Barboza...
Thumbnail

About the event

Image

ESC CONGRESS 2016

27 August - 31 August 2016

Sessions Presentations

This platform is supported by

logo Novo Nordisk